Landmark Initiatives to Boost Ayush Sector Launched in North East India
The highlight of the event was the inauguration of the first-ever dedicated Panchakarma block in the North East region. This facility, situated at CARI, is equipped with modern amenities and will provide Panchakarma therapies to the public at reasonable rates. The Pharmacology & Bio Chemistry lab, another new initiative, was also inaugurated during the event. It will scientifically validate therapeutic and safety potential, develop cost-effective poly herbal formulations, and work towards harnessing the rich biodiversity of the North East region.
Launch of the Traditional Medicine Morbidity codes of Ayurveda, Siddha and Unani Chapter in International Classification of Diseaseas
World Health Organization launch event will be held in New Delhi on 10th January, 2024. The data and terminology relating to diseases based on Ayurveda, Siddha, Unani systems will now be included in the WHOs ICD11 classification.
National Conference on Invisible Disabilities
The conference focuses of sharing experiences, statistical data and formulation of policy regarding invisible disabilities.
WHO to Include Ayurveda, Siddha, Unani Morbidity Codes
The ICD series by WHO serves as a global standard for classifying diseases, providing a common language for health information. While the existing data primarily reflects modern biomedical practices, the upcoming ICD 11 TM Module 2 aims to incorporate data and terminology from Ayurveda, Siddha, and Unani (ASU) systems, bringing global uniformity to the classification of traditional medicine.
New Drug Manufacturing Rules Introduced to Strengthen Quality Standards
The Amendment Rules introduce a new set of guidelines titled “GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS” in Schedule M. The guidelines outline several key principles to be adhered to by pharmaceutical manufacturers, focusing on pharmaceutical quality systems, quality risk management, sanitation and hygiene, qualification and validation, complaints and adverse reactions, product recalls, and change control.
Union Health Minister Inaugurates CDSCO Sub Zonal office & CDTL in Indore
The Central Drug Testing Laboratory, equipped with high-quality laboratory services, will play a crucial role in testing drugs, ensuring the availability of essential and high-quality medicines to improve the health of citizens. The facility is equipped with advanced instruments, including 12 HPLCs, 1 GLC, and 1 UV Spectrophotometer.
Webinar for CGHS Beneficiaries on ‘Ill Effects Of Air Pollution. How To Deal With It.’
The Central Government Health Scheme (CGHS) department under the Ministry of Health and Family Welfare (MoHFW) will orgnaise a webinar on coping with air pollution. This webinar is scheduled to take place on January 9, 2024 at 4pm. The webinar will be held on the topic of ‘Ill Effects Of Air Pollution. How To Deal With It’.
NPPA sets Retail Prices for 19 Formulations
Manufacturers of specific formulations categorized as “new drugs” under the Drug Price Control Order (DPCO), 2013 (DPCO, 2013) are required to set the retail price as indicated in this notification. Manufacturers can add Goods and Services Tax to the retail price only if they have already paid or are liable to pay the government on the mentioned retail price. Manufacturers must issue a price list in Form–V via IPDMS to the National Pharmaceutical Pricing Authority (NPPA) and submit copies to State Drug Controllers and dealers.
Blood Centres Can Only Charge Processing Charges For Blood
The Central Drugs Standards Control Organisation (CDSCO) has issued an advisory requiring adherence to the Revised Guidelines- 2022 for Recovery of Processing Charges for Blood and Blood Components issued by NBTC. The advisory states that during the Drugs Consultative Committee meeting it was opined that blood is not for sale and hence the blood centres shall charge only processing costs.
Over 1 Crore Screened for Sickle Cell Disease under National Sickle Cell Anaemia Elimination Mission
The National Sickle Cell Anaemia Elimination Mission operates in a mission mode, focusing on screening, prevention, and management of sickle cell anemia in all tribal and high-prevalence areas across states and union territories in India. The Ministry aims to build on this momentum, continuing its efforts to reach the set target of screening 7 crore people within the stipulated three-year period.
